Firstwings Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 19-12-2024
- Paid Up Capital ₹ 0.10 M
as on 19-12-2024
- Company Age 5 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 743.29%
(FY 2022)
- Profit 144.60%
(FY 2022)
- Ebitda 47.50%
(FY 2022)
- Net Worth 40.86%
(FY 2022)
- Total Assets 172.92%
(FY 2022)
About Firstwings Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jayakumar Veerappan and Sampath Jeevitha serve as directors at the Company.
- CIN/LLPIN
U51909TN2019PTC132468
- Company No.
132468
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Nov 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Tiruvannamalai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Firstwings Pharma Private Limited offer?
Firstwings Pharma Private Limited offers a wide range of products and services, including Rabies Vaccine, Anti Rabies Injection, Anti Cancer Medicines, Irinotecan Hydrochloride Injection, Pegfilgrastim Injection, Ayurvedic Medicine, Cancer Herbal Medicine, Injectable Products, Pharmaceutical Injectables, Face Mask.
Who are the key members and board of directors at Firstwings Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jayakumar Veerappan  | Managing Director | 08-Nov-2019 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sampath Jeevitha | Whole-Time Director | 08-Nov-2019 | Current |
Financial Performance of Firstwings Pharma.
Firstwings Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 743.29% increase. The company also saw a substantial improvement in profitability, with a 144.6% increase in profit. The company's net worth Soared by an impressive increase of 40.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Firstwings Pharma?
In 2022, Firstwings Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Firstwings Pharma?
Unlock and access historical data on people associated with Firstwings Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Firstwings Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Firstwings Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.